BioSpace News Archive

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

According to QY Research Medical, the organ-on-chip market size was surpassed at $103.44 million in 2020, and is expected to reach $1.6 billion by 2030, growing at a CAGR of 31.5% from 2021 to 2030.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Healthcare Conference.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022.

Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd.

OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix™ HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures.

The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES).

MediCardia Health Inc., a pioneer in global digital health, announced today that the Company has completed integration with Optimize EP’s CaRM CIED (cardiovascular implantable electronic device) platform.

Waters Corporation Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2022 Global Healthcare Conference in New York City on Wednesday, June 8th, 2022 at 4:30PM Eastern Standard Time.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at three upcoming investor conferences.